Héma-Québec, the organization in Quebec that manages blood and biological products, has awarded a two-year tender for TAKHZYRO® (lanadelumab injection), as the sole option for prophylaxis subcutaneous (SC) treatment for Type I/II HAE patients. To learn more, please refer to Takeda’s press release in English and French.
